Welcome to the Winter 2025 Notable New Drugs Report
This edition of the report showcases:
- Two new indications for GLP-1s (obstructive sleep apnea and chronic kidney disease) in patients with type 2 diabetes could mean billions of dollars in additional sales.
- A new cystic fibrosis drug offers a simplified treatment regimen and greater effectiveness against more of the genetic mutations that cause the condition.
- Novel, nonaddictive, non-opioid treatment for acute pain.
Don't want to read the full report? Download the summary.
Related healthcare insights
Article
New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.
![New Options to Treat Schizophrenia, COPD [Report]](/content/dam/o4-dam/images/professionals/pharmacies/clinician-on-ipad-with-microscope-1080x720.jpg)
Report
A clever combination drug offers new help for schizophrenia with reduced side effects, while Dupixent expands its footprint to COPD.
Guide
Cutting-edge research in gene therapy, mRNA editing and blood enzymes pays off with powerful new advances for these drug classes.